CD274 and neoplasm: Based on the correlation between CT image tumor enhancement patterns and tumor mutation burden (TMB), it can predict patients’ response to immunotherapy; based on PET tumor metabolic characteristics and PD-L1 expression levels, it can screen beneficial populations.